Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: Results of a phase II clinical trial

Annals of Hematology

Volumn 85, Issue 9, 2006, Pages 605-609

  Otrock, Zaher K ^a   Azar, Sami T ^a   Shamseddeen, Wael A ^a   Habr, Dany ^b   Inati, Adlette ^c   Koussa, Suzane ^c   Mahfouz, Rami A R ^a   Taher, Ali T ^a,c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Novartis Pharma Services   (Lebanon)

^c Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Clinical trial; Osteoporosis; Thalassemia; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CREATININE; DEOXYPYRIDINOLINE; IRON CHELATING AGENT; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; OSTEOCALCIN; STEROID; TRANQUILIZER; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; AGE; ANALGESIA; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; BONE DENSITY; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR NECK; FEVER; FOLLOW UP; HIP; HUMAN; LUMBAR SPINE; MALE; MEDICAL ASSESSMENT; MORBIDITY; ORAL PARESTHESIA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; OSTEOGENESIS; OSTEOPOROSIS; PROSPECTIVE STUDIES; THALASSEMIA;

EID: 33747828523     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0136-y     Document Type: Article

References (18)

1. Olivieri NF (1999) The beta-thalassemias. N Engl J Med 341:99-109
2. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D (2001) Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 112:36-41
3. Wonke B (1998) Bone disease in beta-thalassaemia major. Br J Haematol 103:897-901
4. Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127-139
5. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12:570-575
6. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J (1995) In: Ando S et al (eds) Endocrine disorders in thalassaemia. Abnormal bone metabolism in thalassaemia. Springer, Berlin Heidelberg New York, pp 39-46
7. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911-915
8. Abdollah Shamshirsaz A, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AA, Aghakhani S, Homayoun H, Larijani B (2003) Metabolic and endocrinologic complications in beta-thalassemia major: A multicenter study in Tehran. BMC Endocrine Disorders 3:4 4
9. Fleisch H (1998) Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100
10. Perifanis V, Vyzantiadis T, Vakalopoulou S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, Harsoulis F (2004) Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. Br J Haematol 125:91-92
11. World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. WHO, Geneva
12. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS (2004) Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 20:309-318
13. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11(Suppl 3):975-977
14. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(Suppl 10):S1-S34
15. Theriault RL (2003) Zoledronic acid (Zometa) use in bone disease. Expert Review of Anticancer Therapy 3:157-166
16. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644-649
17. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123:730-737
18. Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402-408